Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Current Assets (2020 - 2025)

Tarsus Pharmaceuticals has reported Current Assets over the past 6 years, most recently at $522.8 million for Q4 2025.

  • Quarterly results put Current Assets at $522.8 million for Q4 2025, up 46.56% from a year ago — trailing twelve months through Dec 2025 was $522.8 million (up 46.56% YoY), and the annual figure for FY2025 was $522.8 million, up 46.56%.
  • Current Assets for Q4 2025 was $522.8 million at Tarsus Pharmaceuticals, up from $501.7 million in the prior quarter.
  • Over the last five years, Current Assets for TARS hit a ceiling of $522.8 million in Q4 2025 and a floor of $176.0 million in Q4 2021.
  • Median Current Assets over the past 5 years was $253.2 million (2022), compared with a mean of $297.4 million.
  • Biggest five-year swings in Current Assets: soared 110.04% in 2021 and later fell 26.69% in 2023.
  • Tarsus Pharmaceuticals' Current Assets stood at $176.0 million in 2021, then rose by 28.09% to $225.4 million in 2022, then grew by 13.65% to $256.1 million in 2023, then surged by 39.27% to $356.7 million in 2024, then skyrocketed by 46.56% to $522.8 million in 2025.
  • The last three reported values for Current Assets were $522.8 million (Q4 2025), $501.7 million (Q3 2025), and $474.4 million (Q2 2025) per Business Quant data.